AR114482A1 - Anticuerpos injertados con péptido natriurético cerebral - Google Patents
Anticuerpos injertados con péptido natriurético cerebralInfo
- Publication number
- AR114482A1 AR114482A1 ARP190100946A ARP190100946A AR114482A1 AR 114482 A1 AR114482 A1 AR 114482A1 AR P190100946 A ARP190100946 A AR P190100946A AR P190100946 A ARP190100946 A AR P190100946A AR 114482 A1 AR114482 A1 AR 114482A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- fragment
- natriuretic peptide
- brain natriuretic
- amino acid
- Prior art date
Links
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 title abstract 3
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 title abstract 3
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 title abstract 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un anticuerpo, o un fragmento del mismo, que comprende por lo menos una secuencia de aminoácidos heteróloga incorporada en por lo menos una región CDR de dicho anticuerpo o fragmento del mismo, en donde dicha por lo menos una secuencia de aminoácidos heteróloga comprende una secuencia conectora N-terminal (Ntls), un péptido natriurético cerebral (BNP) y una secuencia conectora C-terminal (Ctls). Opcionalmente, por lo menos una porción de dicha por lo menos una región CDR se reemplaza por dicha por lo menos una secuencia de aminoácidos heteróloga incorporada en la misma. La presente se relaciona además con dicho anticuerpo o fragmento del mismo para usar en un método de tratamiento, una composición que comprende dicho anticuerpo o fragmento del mismo, un ácido nucleico o una mezcla de ácidos nucleicos que codifica dicho anticuerpo o fragmento del mismo, una célula huésped que comprende dicho ácido nucleico o dicha mezcla de ácidos nucleicos y con un proceso para producir dicho anticuerpo o fragmento del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167106.6A EP3553082A1 (en) | 2018-04-12 | 2018-04-12 | Brain natriuretic peptide engrafted antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114482A1 true AR114482A1 (es) | 2020-09-09 |
Family
ID=61972397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100946A AR114482A1 (es) | 2018-04-12 | 2019-04-10 | Anticuerpos injertados con péptido natriurético cerebral |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210147504A1 (es) |
| EP (2) | EP3553082A1 (es) |
| JP (2) | JP2021520803A (es) |
| KR (1) | KR20210003788A (es) |
| CN (1) | CN112236197A (es) |
| AR (1) | AR114482A1 (es) |
| AU (1) | AU2019250367A1 (es) |
| BR (1) | BR112020020188A2 (es) |
| CA (1) | CA3096725A1 (es) |
| IL (1) | IL277867A (es) |
| MX (1) | MX2020010699A (es) |
| PE (1) | PE20210019A1 (es) |
| SA (1) | SA520420338B1 (es) |
| SG (1) | SG11202009460VA (es) |
| TW (1) | TW202012437A (es) |
| WO (1) | WO2019197475A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332423A (zh) * | 2021-05-26 | 2021-09-03 | 华中科技大学同济医学院附属协和医院 | 一种pcsk9抑制剂在心脏移植术后抗排斥反应中的应用 |
| CN117430702B (zh) * | 2022-07-21 | 2024-06-21 | 东莞市朋志生物科技有限公司 | 抗b型尿钠肽抗体或其功能性片段、检测b型尿钠肽的试剂和试剂盒 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US20070292411A1 (en) * | 2000-11-08 | 2007-12-20 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AU2002307062A1 (en) * | 2001-04-02 | 2002-10-15 | Purdue Pharma L.P. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2005082004A2 (en) | 2004-02-24 | 2005-09-09 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies having a domain-exchanged scaffold |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| US20080181903A1 (en) | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| US20100310561A1 (en) | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| EP2413969A4 (en) | 2009-03-30 | 2012-09-05 | Boehringer Ingelheim Int | FUSION PROTEINS WITH DOG FC ELEMENTS |
| TWI471137B (zh) | 2009-05-20 | 2015-02-01 | Biomarin Pharm Inc | Ｃ型利鈉胜肽變異體 |
| US20120108514A1 (en) | 2009-07-09 | 2012-05-03 | University Of Iowa Research Foundation | Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
| US9187466B2 (en) | 2010-02-27 | 2015-11-17 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| JP6114189B2 (ja) | 2010-07-09 | 2017-04-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| WO2013007563A1 (en) * | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
| CN103087191A (zh) * | 2012-12-26 | 2013-05-08 | 天健生物制药（天津）有限公司 | 一种抗人NT-proBNP多肽的单克隆抗体及其应用 |
| CN105555310B (zh) * | 2013-07-08 | 2019-07-23 | 南京传奇生物科技有限公司 | 一种提高蛋白血清半衰期的组合物和方法 |
| CA2966256A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
-
2018
- 2018-04-12 EP EP18167106.6A patent/EP3553082A1/en not_active Withdrawn
-
2019
- 2019-04-10 BR BR112020020188-0A patent/BR112020020188A2/pt unknown
- 2019-04-10 CA CA3096725A patent/CA3096725A1/en active Pending
- 2019-04-10 JP JP2020555238A patent/JP2021520803A/ja active Pending
- 2019-04-10 US US17/046,648 patent/US20210147504A1/en active Pending
- 2019-04-10 WO PCT/EP2019/059101 patent/WO2019197475A1/en active Application Filing
- 2019-04-10 SG SG11202009460VA patent/SG11202009460VA/en unknown
- 2019-04-10 AU AU2019250367A patent/AU2019250367A1/en active Pending
- 2019-04-10 AR ARP190100946A patent/AR114482A1/es unknown
- 2019-04-10 MX MX2020010699A patent/MX2020010699A/es unknown
- 2019-04-10 PE PE2020001562A patent/PE20210019A1/es unknown
- 2019-04-10 KR KR1020207032278A patent/KR20210003788A/ko not_active Application Discontinuation
- 2019-04-10 CN CN201980038639.XA patent/CN112236197A/zh active Pending
- 2019-04-10 EP EP19716170.6A patent/EP3773902A1/en active Pending
- 2019-04-10 TW TW108112516A patent/TW202012437A/zh unknown
-
2020
- 2020-10-07 IL IL277867A patent/IL277867A/en unknown
- 2020-10-12 SA SA520420338A patent/SA520420338B1/ar unknown
-
2024
- 2024-02-02 JP JP2024014699A patent/JP2024050761A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202012437A (zh) | 2020-04-01 |
| MX2020010699A (es) | 2020-11-06 |
| SA520420338B1 (ar) | 2024-03-13 |
| CN112236197A (zh) | 2021-01-15 |
| PE20210019A1 (es) | 2021-01-07 |
| EP3553082A1 (en) | 2019-10-16 |
| JP2024050761A (ja) | 2024-04-10 |
| BR112020020188A2 (pt) | 2021-01-19 |
| IL277867A (en) | 2020-11-30 |
| KR20210003788A (ko) | 2021-01-12 |
| JP2021520803A (ja) | 2021-08-26 |
| AU2019250367A1 (en) | 2020-10-29 |
| CA3096725A1 (en) | 2019-10-17 |
| US20210147504A1 (en) | 2021-05-20 |
| SG11202009460VA (en) | 2020-10-29 |
| EP3773902A1 (en) | 2021-02-17 |
| WO2019197475A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101936A1 (es) | Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas | |
| AR120563A1 (es) | Receptores de antígeno quimérico cd19 y cd22 y sus usos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| TN2018000325A1 (en) | ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALL Y BINDING TO CD3 AND/OR CD123. | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| AR105654A1 (es) | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| PE20210342A1 (es) | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos | |
| PE20171111A1 (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| AR095660A1 (es) | Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
| EA201790976A1 (ru) | Терапевтические вакцины против hpv16 | |
| MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
| AR114482A1 (es) | Anticuerpos injertados con péptido natriurético cerebral | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| MX2016010791A (es) | Inmunoterapia con multiples objetivos dirigida por biomarcadores. | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
| PE20201067A1 (es) | Anticuerpos anti-csf 1r | |
| SV2017005545A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos | |
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| AR114481A1 (es) | Anticuerpos injertados con péptido natriurético auricular | |
| UY38672A (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| AR118355A1 (es) | Métodos de fabricación para producir composiciones de anticuerpos anti-tnf | |
| SA520420336B1 (ar) | C أجسام مضادة مُطعمة بببتيد مدر للصوديوم من النوع | |
| MX2021007028A (es) | Anticuerpo anti-il-17a y uso del mismo. |